Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
he present art of drug discovery and design of new drugs is based on suicidal irreversible inhibitors. Covalent inhibition is the strategy that is used to achieve irreversible inhibition. Irreversible inhibitors interact with their targets in a time-dependent fashion, and the reaction proceeds to completion rather than to equilibrium. Covalent inhibitors possessed some significant advantages over non-covalent inhibitors such as covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors, covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased potency than non-covalent inhibitors. Several computational approaches have been developed to simulate covalent interactions; however, this is still a challenging area to explore. Covalent molecular docking has been recently implemented in the computer-aided drug design workflows to describe covalent interactions between inhibitors and biological targets. In this review we highlight: (i) covalent interactions in biomolecular systems; (ii) the mathematical framework of covalent molecular docking; (iii) implementation of covalent docking protocol in drug design workflows; (iv) applications covalent docking: case studies and (v) shortcomings and future perspectives of covalent docking. To the best of our knowledge; this review is the first account that highlights different aspects of covalent docking with its merits and pitfalls. We believe that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].](https://figures.cochat.ai/paper-figures/4c29b35814fb4c5895f870ace31f2ee7/theory-and-applications-of-covalent-docking-in-drug-discovery-merits-and-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
From Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges (2018) · cites this paper as Kumalo et al., 2015
In the citing paper
“However, the majority of covalent algorithms are limited to accurately calculating the binding energy between a nucleophilic protein and an electrophilic small molecule (Fig. 4) [74].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
MethodAutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486 · cited 5×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodInfluentialFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“com/web/ Autodock [60] Glide [61] CovDock [62]”
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 4×
“Zhang et al., reported covalent docking (using GOLD version 4.0) in conjunction with molecular dynamics (MD) simulation (Amber Molecular Dynamics Package version 8.0) to explore the binding mode of peptide aldehyde inhibitors as anti-tumor drugs (Figure 4C,D).”
MethodInfluentialA Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827 · cited 2×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundMethodThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“Examples of covalent inhibitors including their protein target(s) with active-site nucleophile: (A) aspirin; (B) neratinib; (C) rivastigmine; (D) Crystal structure of EGFR kinase domain in complex with neratinib, showing the covalent bond between the receptor and the ligand [27].”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873 · cited 3×
“However, not all drugs bind non-covalently to the active site; there are other categories of drugs, namely the covalent drugs [14].”
BackgroundInfluentialAcetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundAbagyan, R., & Totrov, M. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1052 · Cited by 975 · cited 1×
“Abagyan and Totrov developed a 4D-docking protocol for Internal Coordinate Mechanics (ICM), where the receptor conformation is the fourth dimension [63–65].”
MethodDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
BackgroundGeneralized-ensemble algorithms for molecular simulations of biopolymers
Mitsutake, A., Sugita, Y., & Okamoto, Y. (2001) · Biopolymers · doi:10.1002/1097-0282(2001)60:2<96::aid-bip1007>3.0.co;2-f · Cited by 768
Virtual screening with AutoDock: theory and practice
Cosconati, S., Forli, S., Perryman, A. L., Harris, R., Goodsell, D. S., & Olson, A. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.484460 · Cited by 695 · cited 5×
“The most common docking programs and software include Autodock [31], Autodock Vina [32], GOLD [33] and FlexX [34].”
BackgroundInfluentialBikadi, Z., & Hazai, E. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-15 · Cited by 657 · cited 1×
“org/ CovDock-VS [58] DockingServer [59] http://www.”
Diverse, High-Quality Test Set for the Validation of Protein−Ligand Docking Performance
Hartshorn, M. J., Verdonk, M. L., Chessari, G., Brewerton, S. C., Mooij, W. T. M., Mortenson, P. N., & Murray, C. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061277y · Cited by 625 · cited 3×
“sg/ Gold [41] Dockovalent (Covalent Docking Server) [57] http://covalent.”
BackgroundMethodDocking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
Zhu, K., Borrelli, K. W., Greenwood, J. R., Day, T., Abel, R., Farid, R. S., & Harder, E. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500118s · Cited by 462
Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin.
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., & Smith, W. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36820-5 · Cited by 371 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundChallenges and advances in computational docking: 2009 in review
Yuriev, E., Agostino, M., & Ramsland, P. A. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.1077 · Cited by 350 · cited 1×
“The issues related to receptor flexibility have been extensively reviewed in literature [28,66,67].”
BackgroundCovalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346 · cited 1×
“Tetrahydrolipstatin is another class of covalent inhibitors that inhibits fat absorption [19–22].”
BackgroundInhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
Hadváry, P., Lengsfeld, H., & Wolfer, H. (1988) · Biochemical Journal · doi:10.1042/bj2560357 · Cited by 345
Latest developments in molecular docking: 2010–2011 in review
Yuriev, E., & Ramsland, P. A. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2266 · Cited by 344 · cited 1×
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors [35–40].”
BackgroundGuerciolini, R. (1997) · PubMed · Cited by 331
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301 · cited 1×
“Neratinib (HKI-272) (Figure 1B, D) is a tyrosine kinase inhibitor under investigation for the treatment of breast cancer and other solid tumors [24–26].”
BackgroundAutomated Docking Screens: A Feasibility Study
Irwin, J. J., Shoichet, B. K., Mysinger, M. M., Huang, N., Colizzi, F., Wassam, P., & Cao, Y. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9006966 · Cited by 286 · cited 1×
“sg/ Gold [41] Dockovalent (Covalent Docking Server) [57] http://covalent.”
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
BackgroundMechanistic Basis of Enzyme-Targeted Drugs
Robertson, J. G. (2005) · Biochemistry · doi:10.1021/bi050247e · Cited by 248 · cited 1×
“In recent literature, there has been a growing interest in the design of drugs forming a covalent bond with the target protein, with nearly 30% of the marketed drugs targeting enzymes known to act by covalent inhibition (Table 1) [6,7].”
BackgroundZhu, K., Day, T., Warshaviak, D., Murrett, C., Friesner, R., & Pearlman, D. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24551 · Cited by 236 · cited 1×
“Recent implementation of web based large scale virtual screening (CovalentDock Cloud) with covalent docking capability is a huge boost forward to develop potent covalent inhibitors targeting a variety of diseases using structure based drug design approach [56].”
BackgroundSmith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193 · cited 1×
“,: (i) covalent warheads can target rare, non-conserved residue of a particular target protein and thus led to development of highly selective inhibitors; (ii) covalent inhibitors can be effective in targeting proteins with shallow binding cleavage which will led to development of novel inhibitors with increased poten…”
BackgroundNanoparticle mediated non-covalent drug delivery
Doane, T., & Burda, C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.012 · Cited by 188 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
BackgroundHonarparvar, B., Govender, T., Maguire, G. E. M., Soliman, M. E. S., & Kruger, H. G. (2013) · Chemical Reviews · doi:10.1021/cr300314q · Cited by 187 · cited 1×
“In a recent report, we have highlighted the interface between computational approaches and experiment as crucial tools in the drug discovery machinery [5].”
BackgroundSelf-citationDocking, virtual high throughput screening and in silico fragment‐based drug design
Zoete, V., Grosdidier, A., & Michielin, O. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00665.x · Cited by 184 · cited 1×
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors [35–40].”
BackgroundBottegoni, G., Kufareva, I., Totrov, M., & Abagyan, R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8009958 · Cited by 180 · cited 1×
“Abagyan and Totrov developed a 4D-docking protocol for Internal Coordinate Mechanics (ICM), where the receptor conformation is the fourth dimension [63–65].”
MethodThe Development of HKI‐272 and Related Compounds for the Treatment of Cancer
Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 174 · cited 1×
“Neratinib (HKI-272) (Figure 1B, D) is a tyrosine kinase inhibitor under investigation for the treatment of breast cancer and other solid tumors [24–26].”
BackgroundStructure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands
Warshaviak, D. T., Golan, G., Borrelli, K. W., Zhu, K., & Kalid, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500175r · Cited by 169 · cited 4×
“However, Warshaviak et al., has addressed this issue by the development of CovDock-VS which has shown to be a straightforward and efficient method that can be applied successfully in screening campaigns for covalent inhibitors [58].”
BackgroundMethodInfluentialDrug discovery for a new generation of covalent drugs
Kalgutkar, A. S., & Dalvie, D. K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688744 · Cited by 166 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
BackgroundApplication of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability
Jain, N. K., & Gupta, U. D. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.8.1035 · Cited by 142 · cited 1×
“These types of inhibitors derive their activity from both non-covalent interactions and the formation of the covalent bond between the inhibitor and the target protein [8–13].”
BackgroundOuyang, X., Zhou, S., Su, C. T. T., Ge, Z., Li, R., & Kwoh, C. K. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23136 · Cited by 134
Accessible High-Throughput Virtual Screening Molecular Docking Software for Students and Educators
Jacob, R. B., Andersen, T., & McDougal, O. M. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002499 · Cited by 131 · cited 1×
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors [35–40].”
BackgroundTotrov, M. M., & Abagyan, R. A. (2001) · Biopolymers · Cited by 123
Enzymes as a special class of therapeutic target: clinical drugs and modes of action
Robertson, J. G. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.08.008 · Cited by 88 · cited 1×
“In recent literature, there has been a growing interest in the design of drugs forming a covalent bond with the target protein, with nearly 30% of the marketed drugs targeting enzymes known to act by covalent inhibition (Table 1) [6,7].”
BackgroundRiely, G. J. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e96e · Cited by 75
Dahal, U. P., Obach, R. S., & Gilbert, A. M. (2013) · Chemical Research in Toxicology · doi:10.1021/tx400301q · Cited by 71 · cited 1×
“Tetrahydrolipstatin is another class of covalent inhibitors that inhibits fat absorption [19–22].”
BackgroundDocking-Based Virtual Screening of Covalently Binding Ligands: An Orthogonal Lead Discovery Approach
Schröder, J., Klinger, A., Oellien, F., Marhöfer, R. J., Duszenko, M., & Selzer, P. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3013932 · Cited by 64 · cited 1×
“The most potent inhibitor, 4-(N-phenylanilino)-6-pyrrolidin-1-yl-1, 3, 5-triazine-2-carbonitrile (CP243522) (Figure 5E), showed a Ki of 21nM and was confirmed to have a covalent reversible mechanism of inhibition [53].”
BackgroundProtein Flexibility in Virtual Screening: The BACE-1 Case Study
Cosconati, S., Marinelli, L., Leva, F. S. D., Pietra, V. L., Simone, A. D., Mancini, F., Andrisano, V., Novellino, E., Goodsell, D. S., & Olson, A. J. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300390h · Cited by 55 · cited 1×
“The issues related to receptor flexibility have been extensively reviewed in literature [28,66,67].”
BackgroundAn introduction to biomolecular simulations and docking
Mura, C., & McAnany, C. E. (2014) · Molecular Simulation · doi:10.1080/08927022.2014.935372 · Cited by 54 · cited 1×
“Molecular docking is a computational procedure performed on structure-based rational drug design to identify correct conformations of small molecule ligands and also to estimate the strength of the protein-ligand interaction, usually one receptor and one ligand [28–30].”
MethodKatritch, V., Byrd, C. M., Tseitin, V. M., Dai, D., Raush, E., Totrov, M. M., Abagyan, R. A., Jordan, R., & Hruby, D. E. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9138-7 · Cited by 51 · cited 1×
“Out of 456 predicted ligands, 97 inhibitors of I7L proteinase activity were confirmed to be active in biochemical assays (20% overall hit rate) [44].”
BackgroundLamb, H. M., & Goa, K. L. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119030-00008 · Cited by 51 · cited 1×
“Rivastigmine is a cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type (Figure 1C) [23].”
BackgroundLawandi, J., Toumieux, S., Seyer, V., Campbell, P., Thielges, S., Juillerat-Jeanneret, L., & Moitessier, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901013a · Cited by 49 · cited 2×
“Furthermore, the docking studies (using the FITTED docking engine and defaults parameters) also identified the configuration of the stereo-genic center at the ring junction as a limiting factor for optimal activity of which this can be used to develop second generation of potent inhibitors [45].”
BackgroundMethodStrategies for dealing with reactive intermediates in drug discovery and development.
Nassar, A.-E. F., & Lopez‐Anaya, A. (2004) · PubMed · Cited by 48
Recent Advances in Computer-Aided Drug Design as Applied to Anti-Influenza Drug Discovery
Mallipeddi, P. L., Kumar, G., White, S. W., & Webb, T. R. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929153812 · Cited by 47 · cited 1×
“The issues related to receptor flexibility have been extensively reviewed in literature [28,66,67].”
BackgroundJuhl, P. B., Trodler, P., Tyagi, S., & Pleiss, J. (2009) · BMC Structural Biology · doi:10.1186/1472-6807-9-39 · Cited by 47 · cited 1×
“The method was robust toward small differences in initial structures (different crystallization conditions or a co-crystallized ligand), although large displacements of catalytic residues often resulted in substrate poses that did not pass the geometric filter criteria [48].”
Fragment-Based Drug Design: Computational and Experimental State of the Art
Hoffer, L., Renaud, J., & Horvath, D. (2011) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620711795767884 · Cited by 46 · cited 1×
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors [35–40].”
BackgroundZhu, Y., Zhu, X., Wu, G., Ma, Y., Li, Y., Zhao, X., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901407s · Cited by 39 · cited 1×
“This indicated that they adopted a similar mode to inhibit the 20S proteasome as bortezomib [50].”
BackgroundDocking and 3D-QSAR Studies on Isatin Sulfonamide Analogues as Caspase-3 Inhibitors
Wang, Q., Mach, R. H., & Reichert, D. E. C. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900144x · Cited by 38 · cited 1×
“The study showed that structure-based design methods (such as docking) can cultivate the development of reliable QSAR models [47].”
MethodRoy, K. K., Tota, S., Tripathi, T., Chander, S., Nath, C., & Saxena, A. K. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.005 · Cited by 35 · cited 1×
“The interaction patterns of the two new potent carbamates (Figure 5B,D) were very similar to that of ganstigmine [52].”
ResultZhang, S., Shi, Y., Jin, H., Liu, Z., Zhang, L., & Zhang, L. (2009) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0515-0 · Cited by 34 · cited 1×
“This study contributed to the understanding of the mechanism and structure-activity relationship of the peptide aldehyde inhibitors and may provide useful information for rational drug design [46].”
BackgroundA conceptual framework for computational models of Achilles tendon homeostasis
Smith, D. W., Rubenson, J., Lloyd, D. G., Zheng, M., Fernandez, J., Besier, T. F., Xu, J., & Gardiner, B. S. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1229 · Cited by 34 · cited 1×
“Computational and molecular modeling tools have become a close counterpart to experiment in the understanding of molecular aspects of biological systems [1–4].”
BackgroundIn silico fragment-based drug design
Konteatis, Z. D. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.523697 · Cited by 33
Neto, O. P. V. (2014) · Journal of Computational and Theoretical Nanoscience · doi:10.1166/jctn.2014.3446 · Cited by 30 · cited 1×
“Computational and molecular modeling tools have become a close counterpart to experiment in the understanding of molecular aspects of biological systems [1–4].”
BackgroundHeme prosthetic group required for acetylation of prostaglandin H synthase by aspirin
Chen, Y. P., & Marnett, L. J. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.11.2506093 · Cited by 26 · cited 1×
“However, docking ligands that bind covalently to the receptor has been complicated, because of the reaction between the ligand and the receptor that needs to be taken into consideration [15].”
BackgroundPrediction of Substrates for Glutathione Transferases by Covalent Docking
Dong, G. Q., Calhoun, S., Fan, H., Kalyanaraman, C., Branch, M. C., Mashiyama, S. T., London, N., Jacobson, M. P., Babbitt, P. C., Shoichet, B. K., et al. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5001554 · Cited by 25 · cited 1×
“, showed that covalent docking can be a useful tool for substrate discovery, they investigated the accuracy of docking poses and substrate discovery in the GST superfamily, by docking 6738 potential ligands from the KEGG and MetaCyc compound libraries into 14 representative GST enzymes with known structures and substr…”
BackgroundStructural ensemble in computational drug screening
Fukunishi, Y. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.486399 · Cited by 24 · cited 1×
“The majority of docking methods development research has been focused on the effective prediction of the binding modes of non-covalent inhibitors [35–40].”
BackgroundComputational thermodynamics, computational kinetics, and materials design
Lu, X., Wang, Z., Cui, Y., & Jin, Z. (2014) · Chinese Science Bulletin · doi:10.1007/s11434-014-0219-4 · Cited by 24 · cited 1×
“Computational and molecular modeling tools have become a close counterpart to experiment in the understanding of molecular aspects of biological systems [1–4].”
BackgroundBlake, L., & Soliman, M. E. S. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0822-y · Cited by 20 · cited 1×
“The method was validated by means of MD simulation to ensure that docked complexes are stable and there were no possible docking artifacts [54].”
MethodSelf-citationDocking and Biomolecular Simulations on Computer Grids: Status and Trends
Tantar, A., Conilleau, S., Parent, B., Melab, N., Brillet, L., Roy, S., Talbi, E., & Horvath, D. (2008) · Current Computer - Aided Drug Design · doi:10.2174/157340908785747438 · Cited by 19 · cited 1×
“Molecular docking is a computational procedure performed on structure-based rational drug design to identify correct conformations of small molecule ligands and also to estimate the strength of the protein-ligand interaction, usually one receptor and one ligand [28–30].”
MethodMechanistic Basis of Enzyme-Targeted Drugs
Robertson, J. G. (2005) · Biochemistry · doi:10.1021/bi058007m · Cited by 19
Wells, I., & Marnett, L. J. (1992) · Biochemistry · doi:10.1021/bi00155a002 · Cited by 18 · cited 1×
“The earliest example of a covalent drug is aspirin, which was first marketed over a century ago; aspirin covalently modifies cyclooxygenase by inducing the acetylation of a serine residue that is situated in the active site (Figure 1A) [15–18].”
BackgroundSynthesis and SAR Study of Novel Peptide Aldehydes as Inhibitors of 20S Proteasome
Ma, Y., Xu, B., Fang, Y., Yang, Z., Cui, J., Zhang, L., & Zhang, L. (2011) · Molecules · doi:10.3390/molecules16097551 · Cited by 16 · cited 1×
“The suggested binding mode provides a potential way to design more potent inhibitors of the 20S proteasome [51].”
BackgroundChernorizov, K. A., Elkina, J. L., Semenyuk, P. I., Švedas, V. K., & Muronetz, V. I. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910120047 · Cited by 13 · cited 1×
“Therefore, the compounds were assumed to inhibit the formation of the proapoptotic complex GAPDH–Siah1 and therefore have potential effect against Parkinson’s disease [49].”
Background
Research works printed but not linked: 1
- Ding, 2002, Computational manufacturing, Prog. Nat. Sci., 12, 641
Cited by
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
“Recent reports have claimed that approximately one-third of the currently marketed enzyme modulators are covalent inhibitors [88].”
BackgroundGuedes, I. A., Pereira, F. S. S., & Dardenne, L. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01089 · Cited by 331
“Due to the increasing interest in covalent drugs, many non-covalent docking programs have developed covalent versions and some new docking programs focused on covalent ligands have been developed (Kumalo et al., 2015; Awoonor-Williams et al., 2017; De Cesco et al., 2017).”
BackgroundMethodCovalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
“The rising interest in covalent drugs has resulted in a surge in the development of docking methods to bolster their discovery and design [108].”
BackgroundDocking Screens for Novel Ligands Conferring New Biology: Miniperspective
Irwin, J. J., & Shoichet, B. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02008 · Cited by 277
Molecular Docking for Drug Discovery and Development: A Widely Used Approach but Far from Perfect
Wang, G., & Zhu, W. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0143 · Cited by 175
Metadata
- Authors
- Kumalo, H., Bhakat, S., & Soliman, M.
- Affiliations
- University of KwaZulu-Natal (ZA)
- Corresponding author
- Soliman, Mahmoud
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2015-01-27
- Volume
- 20
- Issue
- 2
- Pages
- 1984-2000
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC6272664
- OpenAlex
- W2029963983
- Cited by
- 158
- References
- 68
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 10 · 2023: 17 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 13 · 2017: 13 · 2016: 19 · 2015: 5
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- Inyuvesi Yakwazulu-Natali
- Center for High Performance Computing
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent docking, covalent inhibitors, irreversible inhibition, computer-aided drug design, covalent interactions, protein-ligand binding, covalent warheads, selective inhibitors
- MeSH terms
- Humans, Protein Binding, Software, Thermodynamics, Drug Discovery, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.